UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **August 14, 2014**

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	**000-50761**	**11-3146460**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

14 Plaza Drive Latham, New York	**12110**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(518) 795-1400**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 – Regulation FD Disclosure.

On August 14, 2014, Joseph M. DeVivo, President and Chief Executive Officer of AngioDynamics, Inc. (the "Company"), will present to certain investors at the Canaccord Genuity 34th Annual Growth Conference. The conference slides are furnished herewith as Exhibit 99.1.

The slides are being furnished pursuant to Item 7.01 and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation slides for the Canaccord Genuity 34th Annual Growth Conference on August 14, 2014.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.

Date: August 14, 2014

/s/ Stephen A. Trowbridge
Stephen A. Trowbridge
Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description	Paper (P) or Electronic (E)
99.1	Presentation slides for the Canaccord Genuity 34th Annual Growth Conference on August 14, 2014.	E

angiodynamics

Joseph M. DeVivo, President and CEO

August 2014

Forward-Looking Statements

Notice Regarding Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic" or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013 and the current report on Form 8-K, filed with the SEC on July 23, 2014. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported non-GAAP sales growth, non-GAAP gross margin, non-GAAP operating income, adjusted EBITDA (income before interest, taxes, depreciation and amortization), non-GAAP net income and non-GAAP earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

angiodynamics

Profile of AngioDynamics

Recognized globally as a leading provider of innovative, image guided, minimally invasive solutions.

Corporate History	**Founded 1988 | IPO May 2004—ANGO (NASDAQ)** Acquired Microsulis (2013) | Vortex Medical (2012) Navilyst (2012) | Oncobionic (2008) | RITA Medical (2007)
Worldwide Presence	Albany NY - HQ | 1,300 Employees | 7 Operating Locations
Global Selling Reach	150+ person direct sales reps in U.S., Australia, Canada, France, Germany, Netherlands and UK 50+ markets through 110+ distributors

angiodynamics

Performance Update

Q4 FY14 Results

	Q4 FY14 Guidance	Q4 FY14 Actual
Sales	$91M-$95M	$94.1M
EPS	$0.18 – $0.21 Adjusted Without Amortization	$0.18 Adjusted Without Amortization

FY14
Revenue
$354.5M

4%	$0.58
Rev. Growth	Adjusted EPS

FY14 Highlights

- Novation BioFlo PICC & BioFlo Port Contract
- CFGs for VA & PV products made in Queensbury, N.Y.
- Celerity Agreement & first U.S. clearance
- BioFlo DuraMax chronic hemodialysis catheter U.S. clearance
- AngioVac expanded indication
- Howard Donnelly elected Chairman
- Opened Distribution Center of Excellence & began construction of New York Center of Excellence
- Received Premier Inc.'s first Supplier Horizon Award in Nursing Category
- ERP implementation completed
- AngioVac CE Mark approval
- BioFlo clinical data
- John Soto appointed Chief Commercial Officer
- New CMS reimbursement for in-hospital thermal vein ablations
- Operational excellence initiative
- BioFlo Ports FDA clearance
- Clinical Devices, B.V. acquisition
- CROES & PROOF patient enrollments
- LIDN agreement
- NICE guidance on varicose veins

angiodynamics

Financial Snapshot



$365M
FY15 Revenue Guidance Midpoint

As of Q4 FY14

angiodynamics

Strategic Imperatives

Innovative Technology

Develop innovative Technology that improves patient outcomes while reducing overall healthcare costs

Above Market Growth

Focus our investments in product categories and geographic markets that offer sustainable, profitable growth

Operational Excellence

Enhance our profitability by driving operation excellence across the entire organization

angiodynamics

Three Global Businesses

Peripheral Vascular
PV

- Fluid Management
- Thrombolytics
- Laser Vein Ablation
- Angiographic Catheters/Drainage

Oncology/ Surgery
O/S

- Thermal Ablation
- Non-Thermal Ablation
- Resection

Vascular Access
VA

- PICCs
- Ports
- Dialysis



angiodynamics

Peripheral Vascular
PV

- Fluid Management
- Thrombolytics
- Laser Vein Ablation
- Angiographic Catheters/Drainage

Oncology/ Surgery
O/S

- Thermal Ablation
- Non-Thermal Ablation
- Resection

Vascular Access
VA

- PICCs
- Ports
- Dialysis

angiodynamics

Peripheral Vascular PV

$1.6B Market

Global Net Sales

$ in millions	FY14	
Fluid Mgmt	$79	
Venous		$55
Thrombus Mgmt.	$14	
Other Core Products	$45	
Total PV	**$193**	

Strategic Objectives

- Reinvigorate NAMIC
- Build Thrombus Management
- Expand EVLT Adoption
- Grow Core

Key Growth Drivers

AngioVac Cannula and Circuit

namic fluid management

VenaCure EVLT Endovenous Laser Treatment System

Large Unmet Opportunity

Peripheral Vascular PV

Venous Thromboembolism (VTE) Incidence

- ~1 Million VTE Events per Year in US
- ~300,000 VTE Deaths per Year in US - #3 cause



Additional:
Annual Incidence

Catheter/Lead RA	200,000
RA Mass	47,000
IVCF Thrombosis	14,000
TV Endocarditis	2,500

Current Options

- Oral Anticoagulation
- Systemic and Catheter Directed Thrombolysis
- Mechanical / PharmacoMechanical
- Surgical Embolectomy

Heit JA, et al. *Blood*. 2005;106:267A.
Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012

angiodynamics

Disruptive VTE Technology

Peripheral Vascular PV





angiodynamics

Disruptive VTE Technology

Peripheral Vascular
PV

- Attractive pricing & higher margins
- Scalable platform for next generation devices
- FDA cleared & CE Mark approved
- Newly expanded U.S. indication

AngioVac
Cannula and Circuit

angiodynamics

Fluid Management Market Summary

Peripheral Vascular
PV

~500M
WW MARKET



~10M
PROCEDURES PER YEAR

U.S. Auto Injectors: A Significant Opportunity



Rapidly converting from manual to automated systems

angiodynamics

Source: Millennium Research Group reports; company analysis

NAMIC Duet—Next Generation API

Peripheral Vascular PV

angiodynamics

Leading Laser Vein Treatment

Peripheral Vascular PV

~240M MARKET

3-5% CAGR

Large Underpenetrated Market Opportunity



- 145,000+ VenaCure EVLT procedures in FY2013
- ANGO has ~28% share of Venous Ablation market and ~65% share of the Laser Ablation market
- Installed base of ~ 4,000 units WW, including ~ 700 new 1470 lasers since launch in June 2011

VenaCure EVLT
Endovenous Laser Treatment System

angiodynamics

Leading Laser Vein Treatment

Peripheral Vascular PV





BEFORE AFTER

- NICE ruling establishes thermal ablation, including laser, as the standard of care for the treatment of varicose veins in the United Kingdom
- New CMS APC includes in-hospital endovenous RF and laser varicose vein ablations, increasing payment for laser by 9% while creating parity for thermal procedures

VenaCure EVLT
Endovenous Laser Treatment System

angiodynamics

Peripheral Vascular
PV

Fluid Management
Thrombolytics
Laser Vein Ablation
Angiographic Catheters/Drainage

Oncology/ Surgery
O/S

Thermal Ablation
Non-Thermal Ablation
Resection

Vascular Access
VA

PICCs
Ports
Dialysis



angiodynamics

Oncology/ Surgery **O/S**

Global Net Sales

$ in millions	FY14
Thermal Ablation	$30
NanoKnife	$14
Resection/Other	$5
Total O/S	$49

Strategic Objectives

- Drive NanoKnife Adoption
- Increase Thermal Ablation Share
- Invest in Clinical Development

Key Growth Drivers

NanoKnife

StarBurst RFA Electrodes

acculis Microwave Tissue Ablation System

Expanding Leadership in Tissue Ablation

Oncology/ Surgery O/S

AngioDynamics offers a full complement of tissue ablation products that provide clinicians maximum choice in treating patients

"The US Nonvascular Interventional Radiology market with the fastest growth and greatest potential is the ablation device market"

- MRG Nov. 2012

angiodynamics

Leading Microwave Ablation Technology

Oncology/ Surgery O/S

4.5 cm x 5.5 cm ABLATION IN 6 MINUTES†



"Everything we wanted in a microwave device..."

-Current AngioDynamics RFA Customer

- 2.45Ghz system for faster tissue penetration
- Single applicator
- Predictable volumes of coagulation
- Attractive pricing and gross margins

†The liver coagulation results are from coagulations performed in ex-vivo animal tissue models.

angiodynamics

Building NanoKnife Clinical Data

Oncology/ Surgery O/S

CROES STUDY

AngioDynamics Partners with Clinical Research Office of the Endourological Society (CROES) NanoKnife Safety and Efficacy Study

A Single-Arm Study Focused on the Ablation of Prostate Cancer

16 PATIENTS TO BE ENROLLED

1 STUDY SITE WORLDWIDE

IDE PROSTATE

FDA Grants Prostate IDE Approval for NanoKnife System

Clinical Study to Evaluate feasibility and short-term safety and effectiveness of the NanoKnife System in the ablation of focal prostate cancer

6 PATIENTS TO BE ENROLLED

2 STUDY SITE WORLDWIDE

angiodynamics

Peripheral Vascular
PV

Fluid Management
Thrombolytics
Laser Vein Ablation
Angiographic Catheters/Drainage

Oncology/ Surgery
O/S

Thermal Ablation
Non-Thermal Ablation
Resection

Vascular Access
VA

PICCs
Ports
Dialysis



angiodynamics

Vascular Access VA

$1.0B Market

Global Net Sales

$ in millions

	FY14
PICCs	$51
Ports	$32
Dialysis	$19
Other	$4
Total VA	$106

Strategic Objectives

- Penetrate & Convert
- Penetrationof IDNs/GPOs
- Grow Int'l from 10% to 25% of revenue
- Clinical Data

Key Growth Drivers

BioFlo

Celerity™ Tip Location

angiodynamics

Large Unmet Opportunity

Vascular Access VA

2.7M PICCs placed by nurses & Physicians in 2012[1]





Symptomatic 3-7.8%

PICC-Related UEDVT Incidence Rates[2, 3]

UEDVT Incidents

81,000-211,000

×

Estimated Cost Per Incident[4]

$11,957

▼

U.S. Cost of Hospital-Acquired DVT

$1B - $2.5B

[1] US MARKETS FOR VASCULAR ACCESS DEVICES 2012 - Millennium Research Group

[2] Evans SR, Sharp JH, Lorraine LH, et al. CHEST 2010 ; 138; 803-810

[3] Cowl CT, et al. Complications and cost associated with parenteral nutrition delivered to hospitalized patients through either subclavian or peripherally inserted central catheters Clinical Nutrition (2000) 19 (4): 237-243

[4] Lissovoy Gd, et al. Cost for Inpatient Care of Venous Thrombosis. Arch Intern Med. 2000;160:31603165.

angiodynamics

BioFlo Technology

Vascular Access VA

BioFlo

Prospective Customer Evaluation of BioFlo*

Hospital	BioFlo PICC Placements	DVTs	DVT RATE
1	167	1	0.6%
2	533	6	1.1%
3	1251	7	0.6%

*Data based on results presented at the Association for Vascular Access 27th Annual Scientific Meeting.

Total DVT Rate

0.7%



angiodynamics

Celerity Tip Location Strategy

Vascular Access VA

Tip location, coupled with our innovative BioFlo technology, will improve our competitive position in the PICC market.

Ease of use

- Use with existing ultrasound



Clinical efficacy

- Three lead EKG-based platform
- Predictable and reliable confirmation

Cost effective

- 50% less cost vs. competitors

✓ **Fall 2013 - Canadian Launch**

✓ **March 6, 2014 - Acquired regulatory control over Celerity platform and rights to next generation technology**

✓ **Mid-summer 2014 - U.S. clearance**

angiodynamics

Expanding BioFlo Platform - Ports

Vascular Access VA

Fig. 1 Concurrent VTE and Cancer Increases the Risk of Death

Probabilty of death within 183 days of initial hospital admission



SEM (Scanning Electron Microscopy) Images

BioFlo Port at 15X magnification
Catheter has no visible thrombus, fibrin sheath, or clot.



Competitor A at 15X magnification
Catheter has significant thrombus, fibrin sheath, or clot.



96%
less Thrombus Accumulation
Compared to non-coated conventional port catheters[3]

angiodynamics

Levitan, N et al. Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those Without Malignancy. Medicine: 1999: 78: 285-291.

Expanding BioFlo Platform - Dialysis

Vascular Access VA

Thrombotic occlusions can occur within 24 hours and are prevalent in up to 40 percent of chronic dialysis patients.[1]

BioFlo DuraMax at 10X magnification
Catheter has minimal visible thrombus, fibrin sheath, or clot.

Conventional Non-Coated Catheter at 10x Magnification
Catheter with thrombus accumulation

Heparin Coated Catheter at 10x Magnification
Catheter with thrombus accumulation

90% Less Thrombus Accumulation

In vitro blood loop model test compared to non-coated conventional catheters based on platelet count.[2]

83% Less Thrombus Accumulation

In vitro blood loop model test compared to a heparin coated dialysis catheter.[3]

1 Whitman ED: Complications associated with the use of central venous access devices. Curr Probl Surg 33: 319-378, 1996
2 The reduction in thrombus accumulation (based on platelet count) is supported by acute in-vitro testing. Pre-clinical in-vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation.
3 Based on benchtop testing performed up to two hours using bovine blood which may not be indicative of clinical results. Data on file

angiodynamics

FY 2013: Flat Sales; 50% GM



angiodynamics

Long-Term: ~10% Sales Growth; 60% GM



angiodynamics

Operational Excellence

$15-18M
TO BE
SAVED
OVER THREE YEARS

- [x] Enterprise resource planning implementation
- [x] Consolidation of N.Y. distribution center
- [ ] Consolidation of N.Y. manufacturing plants
- [ ] Supply Chain Optimization
- [ ] Product rationalization
- [ ] Lean Initiatives

angiodynamics

Fiscal 2014 Fourth Quarter Results

Sales

$ in millions, except per share amounts	Q4 2014 (a)	YOY Growth
WW	$94.1	*4%*
WW (excl. supply agreement)	$92.9	*5%*
Peripheral Vascular[(c)]	$50.9	*6%*
Vascular Access	$28.3	*5%*
Onc/Surg	$13.7	*1%*
U.S. (c)	$73.7	*6%*
Int'l	$19.2	*2%*

	Q4 2014 (b)	YOY Growth
Adjusted EBITDA	$14.7	*7%*
Adjusted EPS	$0.18	--

(a) Days sales for the three months ended February 28, 2014, and February 28, 2013, were 61 and 60 days, respectively.
(b) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, direct costs of the Quality Call to Action program, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, and amortization of intangible assets.
(c) Excludes impact of our supply agreement.

angiodynamics

Fiscal 2015 Guidance

$ in millions, except per share amounts	Adjusted Non-GAAP Q1	Adjusted Non-GAAP Full Year
Sales	$83 — $86	$362 — $368
EPS (a)	$0.08 — $0.12	$0.64 — $0.70

(a) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, direct costs of the Quality Call to Action program, amortization of basis step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, and amortization of intangible assets.

Quarterly Sales Growth Trend



angiodynamics

Investment Summary



angiodynamics

angiodynamics

Balance Sheet and Cash Flow

$ in millions	May 31, 2014	May 31, 2013
Cash and investments	$17.9	$24.0
Net working capital	$80.0	$78.1
Total assets	$800.2	$791.6
Total debt	$142.7	$142.5
Total stockholders' equity	$537.9	$526.8

$ in millions, except per share amounts	12 months ended May 31, 2014	12 months ended May 31, 2013
Cash flow from operations	$25.3	$26.9
CFFO/share	$0.72	$0.77
Free cash flow	$13.5	$14.8

angiodynamics

Adjusted Income Statement[(a)]

$ in millions, except per share amounts	12 months ended May 31, 2014	12 months ended May 31, 2013
Sales	$354.5	$342.0
Gross Margin	50.8%	50.8%
Operating Expenses	$140.6	$130.2
Operating Income	$39.4	$43.5
Operating Margin	11.1%	12.7%
Net Income	$20.6	$22.7
EPS	$0.58	$0.64
EBITDA	$52.2	$57.0

(a) Adjusted results excludes amortization, acquisition & restructurings, QCTA, Inventory step-up, contingent earn out revaluation, debt financing costs, litigation and facility consolidation.

angiodynamics